# Study of TAVO101 in Healthy Volunteers

> **NCT05298046** · PHASE1 · COMPLETED · sponsor: **Tavotek Biotherapeutics** · enrollment: 42 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Experimental: TAVO101
- **OTHER:** Other: Placebo

## Key facts

- **NCT ID:** NCT05298046
- **Lead sponsor:** Tavotek Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-11
- **Primary completion:** 2024-06-01
- **Final completion:** 2024-09-30
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2024-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05298046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05298046, "Study of TAVO101 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05298046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*